Clinical Trials Browser

Interventional × Breast Neoplasms × Aromatase Inhibitors × Clear all

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07222267 2026-04-15

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT05879926 2026-04-02

OFSET

Phase 3 Recruiting

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT07423611 2026-02-20

RACE

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06970912 2026-01-21

DNADalHR

Phase 2 Recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

Breast Neoplasms

NCT06361940 2025-10-14

MAPPER

Phase 2 Recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 3 Completed

315 enrolled 11 charts

Breast Neoplasms

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

Phase 2 Active not recruiting

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04240106 2024-02-16

LUZERN

Phase 2 Completed

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

Breast Neoplasms

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Phase 2 Completed

17 enrolled 5 charts

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

Phase 3 Unknown

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Phase 2 Completed

27 enrolled 13 charts

Breast Neoplasms

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

42 enrolled 13 charts

Breast Neoplasms

NCT02701348 2021-08-06

BARONET

Phase NA Completed

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

Phase 2 Active not recruiting

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT01491737 2020-10-28

PERTAIN

Phase 2 Completed

258 enrolled 18 charts

Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT01950182 2020-07-15

SYSUCC-002

Phase 3 Completed

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

Phase 2 Active not recruiting

Breast Neoplasms

NCT01446159 2020-06-02

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Phase 2 Completed

188 enrolled 32 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02338310 2020-02-17

POETIC

Phase 3 Active not recruiting

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT02970682 2019-07-12

STEM

Phase 2 Completed

Breast Neoplasms

NCT04012918 2019-07-09

CONCEPT

Phase 2 Unknown

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Phase 3 Completed

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast Neoplasms

NCT02769104 2018-01-09

ACCN

Phase 3 Unknown

Breast Neoplasms